News and Trends 19 Jan 2023
Pathalys Pharma brings in $150M for SHPT trials
Pathalys Pharma, Inc. and Launch Therapeutics (Launch Tx) have announced a collaboration to advance phase 3 clinical trials for upacicalcet (designated PLS240 for clinical trials) for the treatment of secondary…